Business Context and Reporting Period
Company: GRAIL, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 16, 2025
Reporting Period: Preliminary financial results for the three months ended September 30, 2025.
GRAIL, Inc. announced a strategic private placement and collaboration with Samsung entities, alongside preliminary Q3 2025 financial results.
Key Financial Metrics
| Metric | Value (Preliminary) |
|---|---|
| Total US Screening Revenue (Q3 2025) | $32.1 million to $33.1 million |
| Total Revenue (Q3 2025) | $35.7 million to $36.7 million |
| Loss from Operations (Q3 2025) | $123.9 million to $126.9 million |
| Cash, Cash Equivalents, Restricted Cash, and Short-Term Marketable Securities (as of Sept 30, 2025) | Approximately $547 million |
| Private Placement Shares Issued | 1,570,308 shares |
| Private Placement Price Per Share | $70.05 |
Material Changes and Strategic Developments
Private Placement and Samsung Collaboration
On October 16, 2025, GRAIL entered into a Stock Purchase Agreement with Samsung C&T Corporation, Samsung Electronics Singapore Pte. Ltd., and Samsung Electronics Co., Ltd. (collectively, "Samsung Investors").
- Transaction: Private placement of 1,570,308 shares of common stock at $70.05 per share.
- Use of Proceeds: General corporate purposes, specifically to support commercialization and reimbursement efforts.
- Collaboration Terms:
- Business Collaboration Agreement: To be executed by January 31, 2026. Grants Samsung C&T exclusive rights to commercialize GRAIL's Galleri test in Korea and obligates Samsung not to commercialize other multi-cancer early detection tests in Korea. Includes a right of first negotiation for Japan and Singapore.
- Strategic and Operational Collaboration: To be executed by January 31, 2026 with Samsung Electronics.
- Closing Conditions: Subject to regulatory approvals (including CFIUS), execution of definitive collaboration agreements by January 31, 2026, and other customary conditions.
Financial Performance Trends
The expected year-over-year increase in screening revenue is driven by:
- Increased volumes from continued commercial ramp-up.
- Expansion of the network of ordering providers.
- Additional commercial partnerships and new promotional campaigns.
- Offsetting Factor: An expected decrease in average sale price.
Cash burn is reported to have improved year-to-date due to revenue growth, margin improvements, and cost optimization savings (including reduced workforce from 2024 restructuring).
Guidance, Risks, and Contingencies
- Regulatory Risk: The private placement closing is contingent on CFIUS clearance and other regulatory approvals.
- Agreement Execution Risk: Definitive collaboration agreements with Samsung must be negotiated and executed by January 31, 2026. Failure to do so could prevent the closing of the private placement.
- Financial Data Status: The financial results provided are preliminary, unaudited, and subject to change. They have not been reviewed by GRAIL's independent registered public accounting firm.
- Forward-Looking Statements: The filing contains forward-looking statements regarding future financial trends, regulatory approvals, and the benefits of the Samsung agreements, which are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the final execution of the Business Collaboration Agreement and Strategic/Operational Collaboration Agreement by the January 31, 2026 deadline.
- Monitor the status of CFIUS and other regulatory approvals required to close the private placement.
- Review the upcoming audited Q3 2025 financial statements to confirm the preliminary revenue and loss figures.
- Assess the impact of the "decrease in average sale price" on future gross margins and profitability.
- Confirm the appointment of the Samsung board observer following the closing of the transaction.